• Explore /
  • Poster
  • / Effect of performance status (ECOG PS) on treatment outcome with second-line (2L) nintedanib (NIN) + docetaxel (DOC) for patients (pts) with lung adenocarcinoma after first-line (1L) immune checkpoint inhibitor (ICI) combination therapy.

Effect of performance status (ECOG PS) on treatment outcome with second-line (2L) nintedanib (NIN) + docetaxel (DOC) for patients (pts) with lung adenocarcinoma after first-line (1L) immune checkpoint inhibitor (ICI) combination therapy.

Abstract Video & Slides Poster

Authors

null

Christian Grohé

Department of Respiratory Diseases, ELK Berlin, Berlin, Germany

Christian Grohé , Thomas Wehler , Sven Henschke , Ina Dittrich , Stefan Hammerschmidt , Christoph Aulmann , Tobias Dechow , Conrad Schiefer , Ingo Zander , Wolfgang Schuette , Judith Atz , Rolf Kaiser

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT02392455

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 9092)

DOI

10.1200/JCO.2022.40.16_suppl.9092

Abstract #

9092

Poster Bd #

79

Abstract Disclosures

Similar Posters

First Author: Christian Grohé

First Author: Christian Grohé

First Author: Lin Wu

First Author: Leijuan Gan